Regeneron will receive $326m to develop a new monoclonal antibody to prevent Covid-19 infection. Credit: Viacheslav Lopatin / Shutterstock.com.
The US Department of Health and Human Services (HHS) has made a grant of more than $1.4bn to Project NextGen to facilitate the development of new vaccines and therapeutics for Covid-19.
ReportsLOA and PTSR Model - Ribociclib Succinate in Pediatric Diffuse Intrinsic Pontine Glioma GlobalData
Preview
来源: Pharmaceutical Technology
ReportsLOA and PTSR Model - pneumococcal (24-valent) vaccine GlobalData
View allCompanies IntelligenceThe National Institute of Allergy and Infectious DiseasesJ LabsICON Government and Public Health Solutions, Inc.Regeneron GmbHHH&S LtdView all
This initiative focuses on progressing vaccines and therapies into clinical trials, and their subsequent regulatory review and commercialisation for use by Americans.
The latest funding includes a $1bn award to four BARDA clinical trial partners, ICON Government and Public Health Solutions, Pharm-Olam, Technical Resources and Rho Federal Systems, to carry out Phase IIb clinical trials of a vaccine.
Global Health Investment (GHIC) will be awarded $100m to advance technologies to expedite future responses.
There is also an award of $10m to Johnson & Johnson Innovation (JLABS) for the Blue Knight initiative, a collaboration between BARDA and JLABS.
HHS Secretary Xavier Becerra stated: “Project NextGen is a key part of the Biden-Harris administration’s commitment to keeping people safe from Covid-19 variants.
“These awards are a catalyst for the programme – kickstarting efforts to more quickly develop vaccines and continue to ensure availability of effective treatments.”